ARTICLE
Quviviq vs Belsomra — the first orexin antagonist against the newest
Same class, same mechanism, eight years apart. What separates them is what a decade of use bought Belsomra, and what newer pharmacology bought Quviviq.
Belsomra (suvorexant) was the first dual orexin receptor antagonist ever approved — August 2014, the drug that established the class. Quviviq (daridorexant) arrived in January 2022 as the newest member of it. They block the same two receptors by the same mechanism, so the familiar new-versus-old framing does not apply here: neither is a different kind of drug.
What separates them is narrower and more useful. Belsomra has roughly a decade of prescribing behind it and is the only orexin antagonist named in the American Academy of Sleep Medicine's pharmacologic guideline. Quviviq has a shorter half-life and less drug left in you by morning. That single difference — half-life — turns out to be both Belsomra's advantage and its liability, and it is where this comparison actually gets decided.
| Quviviqdaridorexant | Belsomrasuvorexant | |
|---|---|---|
| Mechanism | Dual orexin receptor antagonist — blocks both OX1 and OX2 to remove the wake signal; does not sedate | Dual orexin receptor antagonist — blocks both OX1 and OX2, the same mechanism, and the first drug of the class |
| FDA approval | January 2022 — the newest of the three DORAs | August 13, 2014 — the first DORA ever approved |
| Half-life | ~8 hours — the shortest in the class | ~12 hours (mean t½, 95% CI 12–13) |
| Standard dose | 25 mg or 50 mg once nightly, taken within 30 minutes of bed with at least 7 hours before you plan to wake | 10 mg once nightly, taken within 30 minutes of bed with at least 7 hours before you plan to wake; may be increased but not to exceed 20 mg. The 20 mg ceiling was set over next-day driving concerns, not lack of efficacy at higher doses |
| Next-morning residual risk | Lower — the shortest half-life of the class means less drug remaining by morning | Higher — the label states driving ability was impaired in some individuals taking 20 mg, and CNS depressant effects can persist for several days after stopping |
| AASM guideline position | Not named — daridorexant was approved five years after the 2017 guideline was published, so it was never assessed in it | The only orexin antagonist the guideline addresses: a weak recommendation for sleep-maintenance insomnia |
| Cost & generic availability | No generic — roughly $500 a month | No generic either. Cheaper than Quviviq but still expensive. One generic application holds tentative FDA approval only, which does not permit marketing, and the composition-of-matter patent runs to 2029 |
| Dependence & rebound | Low — little signal of tolerance, dependence, or withdrawal across the orexin antagonist class | In completed clinical trials there was no evidence of physical dependence with prolonged use, and no reported withdrawal symptoms after discontinuation |
| Controlled-substance status | Schedule IV | Schedule IV |
| Manufacturer | Idorsia | Merck |
The original versus the newest — what ten years of data buys you
Belsomra was first. When the FDA approved suvorexant on August 13, 2014, no drug of its kind existed — it was the first dual orexin receptor antagonist any regulator had cleared, and it established the class that Dayvigo and Quviviq later joined. Everything the field knows about how these drugs behave in ordinary use over years rather than trial weeks, it learned largely from suvorexant first. Quviviq arrived in January 2022, seven and a half years later, designed with that accumulated understanding available to it.
The most concrete thing a decade bought Belsomra is guideline recognition. When the American Academy of Sleep Medicine reviewed the evidence for its 2017 pharmacologic guideline, suvorexant was the only orexin antagonist old enough to have a body of trial data to assess, and the guideline gave it a weak recommendation for sleep-maintenance insomnia — the trouble-staying-asleep pattern rather than trouble falling asleep. It remains the only DORA the guideline names. It is worth being precise about why: Quviviq's absence is not a judgement against it. Daridorexant was approved five years after that guideline was published. The guideline could not have assessed a drug that did not exist. But if formal guideline support carries weight with you or your prescriber — and for some clinicians it reasonably does — only one of these two has it.
What the newer pharmacology bought Quviviq is a shorter half-life: roughly 8 hours against suvorexant's 12. That is not a marketing distinction. It determines how much drug is still circulating when your alarm goes off, and it is the reason daridorexant tends to leave the least next-morning residue of the three. So the trade is legible. On one side, a decade of real-world use and the only guideline recommendation in the class. On the other, cleaner pharmacology and better mornings. Neither of these is straightforwardly the better drug, and on price neither rescues you — both are brand-only, and there is no generic version of either.
When Belsomra makes sense
Belsomra fits best when your insomnia is a maintenance problem. If you fall asleep without much trouble but surface at 3am and cannot get back down, a drug that is still working at that hour is doing something a faster-clearing one cannot. The roughly 12-hour half-life that creates Belsomra's morning question is the same property that gives it reach into the second half of the night, and this is the one place where being the longer-lasting drug is straightforwardly an advantage. It is also the pattern the AASM guideline specifically addresses — the weak recommendation for suvorexant is for sleep-maintenance insomnia, not for insomnia in general.
The second argument is evidence and cost together. Ten years of prescribing means prescribers know this drug, its interactions are well mapped, and its behaviour outside the trial population is documented rather than inferred. On price, Belsomra is cheaper than Quviviq's roughly $500 a month, broadly in the same range as Dayvigo's ~$350 — real relief, but not transformative, and no generic exists for any of the three. If you are on Quviviq largely because it is the newest thing available, the older drug with guideline backing and a lower price is a legitimate question to raise with your prescriber rather than a step backwards.
When Quviviq makes sense
Quviviq fits when your mornings matter as much as your nights. If you drive early, operate machinery, care for young children before dawn, or simply cannot afford to be foggy at 8am, the shortest half-life in the class is the relevant fact. Roughly 8 hours means substantially less drug in you at waking than 12 does, and less next-morning impairment is the single clearest thing daridorexant offers over suvorexant. This matters most if your problem is getting to sleep rather than staying asleep — you need the drug to work at midnight, not at 5am, and anything still circulating after that is cost without benefit.
It also matters if you have already tried Belsomra and the mornings were the reason you stopped. Next-day grogginess is a common reason people abandon a sleep medication that was otherwise working, and switching within the class to the shorter-acting option is a rational response to that specific complaint. The arguments against are cost and evidence base. Quviviq runs around $500 a month with no generic, which is more than Belsomra, and it carries no guideline recommendation — again, because of when it was approved rather than because it was assessed and found wanting. You are paying more for a cleaner next-day profile, not for a more effective drug.
The half-life and next-day question — why Belsomra is capped at 20 mg
This is the concrete safety difference between the two, and it has a documented history. When Merck sought approval for suvorexant, it proposed higher doses than the ones that eventually reached the market. In May 2013 the FDA's advisory committee reviewed the data and rejected the 40 mg dose, citing next-day residual sleepiness and impaired driving performance. The agency ultimately approved the drug with a starting dose of 10 mg and a maximum of 20 mg. The cap was not set because higher doses failed to work — they were studied and they had effect. It was set because of what remained in people the following morning.
The caution did not stop at the higher doses. Belsomra's own prescribing information states that in a study of healthy adults, driving ability was impaired in some individuals taking 20 mg — the approved maximum, not an experimental dose. The label also notes that CNS depressant effects may persist in some patients for up to several days after discontinuing, and that impairment can occur without the person noticing it, which is the part worth sitting with: not feeling groggy is not evidence of being unimpaired. Both drugs carry the same structural instruction for this reason — take the dose within 30 minutes of going to bed, and only when you have at least 7 hours before you plan to wake up.
Here is the tension that makes this comparison genuinely difficult rather than a simple ranking. The 12-hour half-life is why Belsomra can hold you through a 4am waking, and it is also why the FDA limited its dose over driving. It is one property producing both the benefit and the risk, and you cannot take the first without the second. Quviviq's roughly 8 hours reverses the same trade: less morning residue, less reach into the far end of the night. Which side of that you want is not a question about drug quality. It is a question about which half of your night is actually broken, and it is exactly the kind of judgement a prescriber should be making with you rather than a decision to reach on your own.
The honest part — neither one is a cure
Both of these drugs manage a symptom, and only while you keep taking them. Belsomra and Quviviq block the same wake signal by the same mechanism, and choosing between them adjusts your half-life, your monthly cost, and how you feel at 8am. It does not change why you cannot sleep. The orexin antagonists are a genuine improvement on the older sedatives when it comes to dependence — Belsomra's trials showed no evidence of physical dependence with prolonged use and no reported withdrawal symptoms on stopping, which is not a small thing. But a drug with a better safety profile is still a drug you are taking every night for a problem it is not resolving.
This matters most if your nights are the 'tired but wired' kind — an exhausted body and a nervous system that will not switch off. That hyperarousal is what keeps you awake, and turning down one wake signal for eight hours or twelve does not retrain it; tired but wired explains the mechanism. The treatment that does retrain the sleep system — and the one recommended first-line for chronic insomnia, ideally used alongside any medication rather than instead of it — is not a pill. It is CBT-I, and the 6-week program is that treatment delivered as a structured, week-by-week path. For the wider set of options beyond these two drugs, the full Quviviq alternatives guide maps them out.
The full Quviviq alternatives guide — the wider map, including the out-of-class prescription options and why CBT-I remains first-line.
Quviviq vs Dayvigo — the other in-class comparison, where half-life is again the deciding factor but the numbers run the opposite way.
Quviviq vs Ambien — the cross-class comparison, if what you are really weighing is an orexin antagonist against an older sedative.
The strongest OTC sleep aids, ranked honestly — the pillar guide to the non-prescription landscape, if a milder approach is what you are weighing.
Tired but wired — the hyperarousal pattern that neither of these drugs resolves on its own.
The 6-week program — CBT-I as a structured path, the treatment recommended first-line for chronic insomnia.
Frequently asked questions
Is Belsomra better than Quviviq?
Neither is better in the abstract — they are the same class and the same mechanism, and they differ mainly in half-life and evidence base. Belsomra is ahead on two things: it is the only orexin antagonist the AASM pharmacologic guideline names, with a weak recommendation for sleep-maintenance insomnia, and it has roughly a decade of real-world use behind it. Quviviq is ahead on next-morning residue: its half-life of about 8 hours against Belsomra's 12 means less drug left in you at waking, and the FDA capped Belsomra's dose at 20 mg specifically over next-day driving impairment. If your problem is staying asleep, Belsomra's longer reach is an argument for it. If your mornings are the problem, Quviviq's shorter half-life is an argument the other way.
Can you switch from Belsomra to Quviviq?
Yes, and it is a reasonable switch to raise with a prescriber — most often when Belsomra is working at night but leaving next-morning grogginess, which the shorter half-life directly addresses. Because both drugs are in the same class and work by the same mechanism, the switch is more straightforward than moving between drug classes, and neither carries the rebound insomnia that makes leaving a Z-drug difficult: Belsomra's trials showed no evidence of physical dependence and no reported withdrawal symptoms after stopping. It is still a prescription change and belongs with a clinician, who will also weigh the reverse direction — if you are switching because Quviviq is not holding you through the night, the longer-acting drug may be the better fit rather than the worse one.
Which is cheaper, Quviviq or Belsomra?
Belsomra is cheaper, but not dramatically. Quviviq runs around $500 a month; Belsomra sits broadly in the same range as Dayvigo's roughly $350 — meaningfully less, but still expensive for a nightly medication. Neither has a generic, so there is no inexpensive version of either to switch to. For most people the deciding factor is not the list price but what their plan covers, and coverage for the orexin antagonists is inconsistent enough that the only useful answer comes from checking your own formulary. If cost is the main reason you are comparing these two, that is worth saying plainly to your prescriber, because the options that would actually change your monthly bill are mostly outside this drug class.
Which is better for staying asleep?
Belsomra has the stronger case here, on two independent grounds. Its half-life of around 12 hours means it is still active in the second half of the night, when a shorter-acting drug has largely cleared — which is the specific problem if you fall asleep normally but wake at 3am. And the AASM pharmacologic guideline's weak recommendation for suvorexant is for sleep-maintenance insomnia specifically, which is the formal version of the same point. Quviviq's roughly 8-hour half-life is better suited to trouble falling asleep, where you need the drug early and want it gone by morning. The trade-off is real in both directions: the property that lets Belsomra hold you at 4am is also why the FDA limited its maximum dose over next-day driving impairment.
Is there a generic for Belsomra?
No. Despite what several sites suggest, there is no generic suvorexant on the US market. FDA records show one generic application, which holds tentative approval only — a designation meaning the FDA considers the product approvable but that it cannot legally be marketed while patent protection stands. Belsomra's composition-of-matter patent runs to November 2029, with a later formulation patent extending beyond that. The only finished suvorexant product sold in the United States is Merck's brand. The same is true across the class: none of the three orexin antagonists — Quviviq, Belsomra, or Dayvigo — has a generic available, which is why switching between them changes your monthly cost only modestly.
Sources
- U.S. Food and Drug Administration (FDA) — Prescribing Information for QUVIVIQ (daridorexant), Idorsia Pharmaceuticals: dual orexin receptor antagonism, Schedule IV status, ~8-hour half-life, 25 mg / 50 mg dosing, and class warnings (next-day somnolence, complex sleep behaviors).
- U.S. Food and Drug Administration (FDA) — Prescribing Information for BELSOMRA (suvorexant), Merck Sharp & Dohme: dual orexin receptor antagonism at OX1R and OX2R, Schedule IV status, mean terminal half-life of approximately 12 hours (95% CI 12–13), the 10 mg recommended dose and 20 mg maximum taken within 30 minutes of bed with at least 7 hours before awakening, the finding that driving ability was impaired in some individuals taking 20 mg, and Section 9.3 reporting no evidence of physical dependence with prolonged use and no withdrawal symptoms after discontinuation.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349. Source for the weak recommendation for suvorexant in sleep-maintenance insomnia.
- De Crescenzo F, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–184.
- Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125–139.